Sefin

Quick links to important sections

Sefin

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sefin

Overview of Sefin

Sefin is a pharmaceutical medication containing the active ingredient cefuroxime. It belongs to a class of drugs known as second-generation cephalosporin antibiotics. These medications are used to treat various types of bacterial infections by interfering with the way bacteria build their protective cell walls.

Mechanism of Action

As a bactericidal agent, Sefin works by inhibiting the synthesis of the bacterial cell wall. Bacteria require a strong wall to survive in the human body; without it, the cell membrane ruptures, leading to the death of the microorganism. This mechanism is specific to bacteria and does not affect human cells, which do not possess cell walls.

Indications and Usage

Sefin is prescribed for the treatment of infections caused by susceptible strains of designated microorganisms. It is effective against a broad spectrum of both Gram-positive and Gram-negative bacteria. Common conditions for which it may be utilized include:

  • Respiratory Tract Infections: Such as secondary bacterial infections of bronchitis or pneumonia.
  • Ear, Nose, and Throat Infections: Including otitis media, sinusitis, and tonsillitis.
  • Urinary Tract Infections: Bacterial infections affecting the bladder or kidneys.
  • Skin and Soft Tissue Infections: Such as cellulitis or impetigo.
  • Lyme Disease: Early-stage treatment to prevent the progression of the infection.

Characteristics

Sefin is known for its stability against many beta-lactamase enzymes, which are substances produced by certain bacteria to resist the effects of antibiotics. This stability allows the medication to remain effective against bacterial strains that might be resistant to earlier generations of penicillin or other cephalosporins.

Regulatory References

  1. NIH StatPearls

What side effects are possible with Sefin?

Possible Side Effects and Safety Information for Sefin

This section outlines the officially documented adverse reactions and safety information for Sefin, strictly as reported in authoritative government regulatory documents.


Adverse Reaction Scope

Key Adverse Reaction Categories: Adverse reactions are formally classified by the frequency of their occurrence in clinical trials and are organized by System-Organ-Class (SOC) to show which body systems are affected.

Frequency Classification: Regulatory documents use standard frequency bands to categorize reactions, including: Very common (1/10), Common (1/100 to < 1/10), Uncommon (1/1,000 to < 1/100), Rare (1/10,000 to < 1/1,000), Very rare (< 1/10,000), and Not known (cannot be estimated from available data).

System-Organ Classes Involved: Adverse reactions are grouped by body systems, which can include Nervous System Disorders, Gastrointestinal Disorders, Immune System Disorders, and Skin and Subcutaneous Tissue Disorders.

Serious Adverse Reactions: Events defined as Serious include those that result in death, are life-threatening, require initial or prolonged hospitalization, or result in persistent or significant disability/incapacity or a congenital anomaly/birth defect.

Safety-Related Restrictions or Limitations (Contraindications): Formal Contraindications prohibit the use of Sefin under specified conditions, such as known prior hypersensitivity reactions to the product components.


Regulatory Safety Structure

Regulatory Safety Summary:

  • Controlling Restrictions: Official restrictions (Contraindications) are established to prohibit use in circumstances where the risk profile is deemed unacceptable.
  • Systemic Risk Mapping: The overall adverse reaction profile is structurally mapped by the body systems involved (System-Organ-Classes) for comprehensive risk assessment.
  • Risk Magnitude Quantification: The likelihood of non-serious adverse reactions is statistically quantified through formal frequency classifications.
  • Highest Consequence Events: Critical outcomes are categorized as Serious Adverse Reactions, which require specific regulatory focus and monitoring.

Context-of-Use Safety Notes: Safety information specifies the need for periodic monitoring of specific laboratory values and clinical parameters during treatment, as defined in the official prescribing information.

Overdose and Emergency Response

Overdose and When to Seek Help for Sefin (Cephradine)

The official regulatory prescribing information for Sefin (Cephradine) addresses the subject of overdosage by noting a lack of specific clinical data. Certain regulatory labels state that the effects of overdosage are formally "None known." Other official drug information similarly documents that "no relevant data is available on overdosage" for this product. This regulatory statement reflects the status of documented clinical manifestations in official sources, meaning that specific overdose signs or physiological effects are not officially detailed in the labeling.

Mandatory Emergency Response

Regardless of the absence of documented manifestations, all cases of suspected or known overdosage require immediate and specific regulatory action. The official prescribing guidance mandates that you seek immediate medical attention following any overexposure. This is required because professional medical assessment is necessary to manage any potential complications that may arise.

Supportive Management

Treatment for overdosage is officially described as being non-specific. Management must involve the institution of symptomatic treatment and general supportive measures. The purpose of these actions is to maintain stability and address any clinical consequences as they emerge, which is the full scope of treatment formally described in the regulatory overdose section. No specific antidote is documented in the official labeling.

Therapeutic Uses of Sefin

Sefin, which contains the active ingredient cefradine, is considered relevant within the therapeutic domain of first-generation cephalosporins. This medicine is commonly used to help with a wide range of susceptible bacterial infections throughout the body.

First-generation agents like cefradine are applied in addressing symptoms related to physical discomfort arising from infections of the skin and soft tissue, respiratory tract (such as bronchitis and pneumonia), genitourinary tract (such as uncomplicated urinary tract infections), and conditions presenting with episodic or fluctuating manifestations like otitis media (ear infections). When used for these indications, Sefin provides support that helps ease the overall symptom burden and assists with maintaining functional stability during periods of heightened symptoms. This medicine is often applied in scenarios where additional management of discomfort is required. Its application is relevant for easing discomfort.

“This approach contributes to improved comfort during periods of heightened symptoms.”

This therapeutic approach is relevant when supportive symptom management is appropriate and may help patients cope more steadily with temporary physiological imbalance.

Quick Fact: Helps with symptoms related to systemic imbalance

Regulatory References

  1. NIH StatPearls overview on Cephalosporins

Eligibility and Restrictions for Use

The eligibility for using Sefin (Cephradine) is strictly defined by regulatory documents, with rules based on patient history, age, and organ function.

Eligibility Scope

Category Regulatory Statement Status
Absolute Contraindication Hypersensitivity to Cephradine or any cephalosporin antibiotic. Prohibited
Caution Required Known allergy to penicillins (due to cross-allergenicity). Conditional
Organ Function Markedly impaired renal function. Restricted
Comorbidity History of gastrointestinal disease, particularly colitis. Conditional
Age Infants younger than 9 to 12 months. Use Not Established

Eligibility-Related Restrictions

Contraindicated populations must not use Sefin, as mandated by regulatory labeling, if they have a known hypersensitivity to the drug or to the cephalosporin class of antibiotics. The risk of cross-allergenicity also means patients with a severe penicillin allergy should use the medicine with great caution [1.1, 1.2].

Conditional use applies to patients with impaired renal function [2.1]. Because Cephradine is eliminated primarily by the kidneys, patients with marked impairment require close observation and potential dosage adjustment [3.2]. Older adults may also fall under this restriction due to age-related decline in kidney function [3.2].

Regarding age, Sefin is generally allowed for adults and children over nine months [3.3]. However, its safety is not established in infants younger than 9 to 12 months, and no adequate efficacy information exists for this group [4.2].

For pregnancy, the drug was formerly classified as Category B, indicating that use should be conditional and based only on a clearly established need, as human data remain insufficient [2.1]. It passes into breast milk and should be used with caution while nursing [2.2].

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation identifies specific patterns of interaction for Sefin (Cephradine), primarily related to its elimination pathway and pharmacodynamic effects.

Documented Drug-Drug Interactions

Interacting Substance Official Interaction Outcome
Probenecid Co-administration is a pharmacokinetic interaction that raises Cephradine serum concentrations by reducing its renal clearance.
Loop Diuretics (e.g., Furosemide) Concomitant use with other nephrotoxic agents may increase the risk of nephrotoxicity.
Other Nephrotoxic Drugs (e.g., Aminoglycosides) Leads to additive nephrotoxic effects.
Oral Anticoagulants (e.g., Warfarin) May be associated with a fall in prothrombin activity, increasing the risk of bleeding.
Live Bacterial Vaccines May decrease the effectiveness of the vaccine.

Non-Drug Product and Administration Requirements

The regulatory label includes specific restrictions regarding non-medicinal products. Supplements containing Zinc are documented to interfere with the oral absorption of Cephradine, which may reduce its effectiveness. Therefore, a mandatory separation of at least three hours between the oral administration of Cephradine and any zinc-containing supplement is required.

Population-specific cautions are noted for elderly patients and those with renal impairment, as these groups have a documented increased susceptibility to interaction risks, such as nephrotoxicity, due to Cephradine's dependence on kidney excretion.

Mechanism of Action

Sefin (Cephradine) is a bactericidal antibiotic that acts through a precise, multi-step molecular process aimed exclusively at dismantling the structural integrity of susceptible bacteria.


Irreversible Disruption of Bacterial Cell Wall Assembly

The drug's primary action is rooted in its ability to covalently bind to and covalently inactivate Penicillin-Binding Proteins (PBPs), which are transpeptidase enzymes located in the bacterial membrane. These enzymes are essential for the final cross-linking of the peptidoglycan chains, the rigid structural component of the bacterial cell wall. By blocking this crucial assembly step, the drug initiates a structural cascade that disrupts the mechanical stability of the microbial cell wall.


Causal Cascade Leading to Osmotic Lysis

Inactivating the PBPs results in a fundamentally flawed and structurally weak cell wall. This failure prevents the cell from counteracting its significantly high internal osmotic pressure. The subsequent pressure imbalance causes the cell to swell and ultimately rupture (lysis), leading to the lysis and death of the pathogen—the core bactericidal effect.


Mechanistic Constraints and Target Modification

The drug's mechanism is fundamentally constrained by bacterial defense mechanisms, primarily the production of beta-lactamase enzymes, which chemically destroy the Cephradine molecule before it can reach its PBP target. Furthermore, alterations in the structure of the target PBPs can also reduce the drug's binding affinity, thereby limiting the efficacy of the lytic cascade.

Dosage and Administration Information

Sefin (Cephradine) is administered via either the oral route (capsules or suspension) or the parenteral route (Intravenous or Intramuscular injection), with the choice of route often guided by the context of the medical need. The adult oral dosing pattern is 250 mg every six hours or 500 mg every twelve hours. For severe or chronic infection, the dose may be increased, with the maximum parenteral dose reaching up to 8 g per day.

The administration schedule adheres to a strict frequency pattern, requiring doses to be taken at defined intervals (every 6 or 12 hours) to maintain consistency. Sefin may be taken without regard to meals, as food does not impact the total amount of medicine absorbed.

A critical rule for proper use involves physiological adjustment: the dosage must be reduced in individuals with renal impairment. This reduction is calculated based on the patient’s Creatinine Clearance (CrCl) values to prevent accumulation.

Pediatric administration is weight-based, typically 25–50 mg/kg/day, given in divided doses every 6 or 12 hours, with a maximum daily limit of 4 g. Furthermore, the overall duration of administration is stipulated to continue for a minimum of 48 to 72 hours after the patient becomes asymptomatic, and specifically 10 days for streptococcal infections, to meet the standard for treatment completion. The parenteral powder requires reconstitution with a sterile diluent prior to use.

Recent Clinical Evidence

Research Evidence Overview for Sefin (Cephradine)

Evidence for Use in Urinary Tract Infections (UTIs)

The research record for Sefin (Cephradine) in conditions characterized by acute urinary tract infections relies on both historical Randomized Controlled Trials (RCTs) and various comparative clinical studies. These studies primarily examined adult populations, focusing on those with uncomplicated infections.

Researchers focused on bacteriological eradication (clearing the infectious organism) and the assessment of clinical response, which documents how outcomes related to physical discomfort and functional imbalance were measured and tracked during the study period. Comparative studies reported patterns related to short-term outcomes when Cephradine was evaluated against other established antibiotics of the time.

Evidence for Use in Skin and Soft Tissue Infections (SSTIs)

The evaluation of Sefin for infections of the skin and underlying soft tissues involves clinical trials and comparative studies where the drug was studied for conditions like cellulitis and abscesses. Researchers primarily monitored two main outcomes: clinical response, which measured the improvement or resolution of local infection signs, and bacteriological response.

Some research highlights patterns observed in achieving an assessed short-term response. A key limitation is that many supporting studies are historical, and the research does not definitively address the relevance of findings against certain highly resistant bacteria that have become more prevalent in recent years.

Gaps, Uncertainty, and Limitations in the Research Record

The existing evidence base for Sefin presents several research limitations. Primarily, the evidence quality varies across studies, with many foundational trials being older and potentially having smaller sample sizes than required by current regulatory standards. Data for certain groups remain insufficient, and the evidence mainly describes the effectiveness observed during and immediately after the acute treatment phase. Therefore, the research provides context but not individual predictions, and highlights what is known—and what is still uncertain—about its place in the broader evidence landscape.

Key Studies & References

  1. NIH StatPearls: Cephalosporins (Cefradine Classification and General Purpose)
  2. NIH StatPearls: Cephalosporins (Indications and Therapeutic Domain Overview)

Frequently Asked Questions (FAQ)

Common questions about Sefin (FAQ)


Q: How quickly should I expect Sefin to start working?

A: Sefin is known to be rapidly absorbed after oral administration, with the highest concentration in the blood usually reached within about one hour. The onset of clinical effectiveness, which is the lessening of symptoms, will vary based on the infection being treated, and clinical response should be monitored by a healthcare provider.

Q: What are the most common side effects people report when taking Sefin?

A: Official reports indicate that the most common side effects for this group of antibiotics are typically related to the gastrointestinal system. These frequently reported issues can include diarrhea, nausea, and vomiting. Reactions affecting the skin, such as rash or itching, are also among the adverse events that have been reported.

Q: What happens if I accidentally miss a dose of Sefin?

A: Regulatory guidelines emphasize the importance of taking Sefin doses at strictly defined, regular intervals to ensure the medication remains at a consistent, effective level in the body. Patients are generally advised to contact their healthcare professional for specific guidance regarding missed doses.

Q: How long does Sefin stay in your system after you stop taking it?

A: The drug's mean plasma elimination half-life is relatively short. However, because Sefin is primarily cleared by the kidneys, the complete clearance time is influenced by individual factors, particularly kidney function, as indicated in the official product information.

Q: Is it normal to feel a mild headache when first starting Sefin?

A: Headache is listed among the adverse reactions reported for this medication, grouped under general Nervous System Disorders. Any new or concerning symptoms should be reported to the prescribing healthcare professional.

Q: Does Sefin affect the liver or kidneys?

A: Sefin is primarily eliminated by the kidneys, which means caution and dose adjustments are often required for people with pre-existing kidney impairment. Official reports also mention that transient (temporary) elevations in liver enzyme levels have been noted as an adverse reaction.

Q: Are there any long-term side effects associated with Sefin use?

A: Official prescribing information states that the prolonged use of this class of antibiotics may lead to the overgrowth of non-susceptible organisms. Due to this risk, the duration of therapy is generally limited to the period necessary to treat the acute infection.

Q: Is Sefin safe for someone with a history of stomach issues?

A: Regulatory documents indicate that Sefin must be used with caution if a patient has a history of gastrointestinal disease, particularly a condition called colitis. The warning is due to the potential risk of Clostridium difficile-associated diarrhea (CDAD), which is a serious condition associated with antibiotic use.

Q: Is Sefin safe for people with diabetes?

A: Sefin is not directly contraindicated for people with diabetes. However, regulatory information for this class of antibiotics notes that they can sometimes cause false positive results when using certain laboratory tests for urine glucose (sugar). Patients with diabetes are generally advised to discuss this potential issue with their healthcare provider.

Q: What other health conditions make taking Sefin risky?

A: Sefin is formally contraindicated (prohibited) if a patient has a known allergy to cephalosporin or penicillin antibiotics. Caution is also strictly advised for patients with impaired renal function (kidney issues) and a history of colitis.

Q: Is there a generic version of Sefin available?

A: Yes, the active ingredient in Sefin, which is Cephradine (or Cefradine), is widely available as a generic product. Generic versions contain the same active medicinal compound as the brand-name product.

Q: Does Sefin cause drowsiness or make you tired?

A: While the official documentation does not list drowsiness or fatigue as common side effects, other effects on the nervous system, such as dizziness, have been reported. It is important to monitor how the medication affects your body.

Q: What are the signs of a severe allergic reaction to Sefin?

A: Signs of a severe allergic reaction that require immediate medical attention may include swelling of the face or throat (angioedema), severe hives, or difficulty breathing (anaphylaxis). Hypersensitivity reactions are considered serious adverse events.

Q: Is Sefin habit-forming or addictive?

A: Sefin (Cephradine) is an antibiotic and is not listed as a controlled substance by major regulatory bodies. Because of this classification, Sefin is not considered to have abuse or dependence potential.

Q: Are there any restrictions on driving or operating machinery while on Sefin?

A: Because some individuals have reported side effects like dizziness while taking Sefin, caution is generally recommended. If symptoms like dizziness occur, individuals should exercise caution regarding activities such as driving or operating machinery.

Q: What is the best time of day to take Sefin?

A: According to regulatory information, Sefin can be taken without regard to meals (with or without food). The most important instruction is to consistently adhere to the prescribed frequency pattern (e.g., every 6 hours) to keep drug levels stable.

Q: Can Sefin be used during pregnancy or while breastfeeding?

A: Use during pregnancy is typically based on a clear medical need, as human data are often limited. The drug is known to pass into breast milk in small amounts, and the use of Sefin while nursing is typically approached with caution by healthcare providers.

Q: Will Sefin interfere with my yearly flu shot or other vaccinations?

A: The official product label specifically warns that Sefin may potentially decrease the effectiveness of certain live bacterial vaccines. Patients are generally advised to inform their healthcare provider about all current medications, including Sefin, before receiving any vaccination.

Q: Can Sefin cause changes in mood or anxiety?

A: Adverse reactions that affect the central nervous system (CNS) have been reported for this class of antibiotics. While specific changes in mood or anxiety are not commonly listed, CNS effects such as agitation or confusion are covered in the safety profile.

Q: What are the inactive ingredients in Sefin?

A: Official regulatory documents contain a complete list of inactive ingredients for each specific formulation of Sefin (capsule, suspension, injection powder). This information is provided to help patients identify potential non-active allergens or compounds in the final drug product.

Q: If I have allergies, am I more likely to react to Sefin?

A: The highest risk of reaction is for patients with a known allergy to other cephalosporin antibiotics or to penicillins. Patients with these specific drug allergies are advised to use Sefin with caution due to the possibility of cross-allergenicity.

Q: Do you need to stop taking Sefin gradually, or can you just quit?

A: The drug must be taken for the full prescribed duration to ensure the infection is fully resolved and to prevent antibiotic resistance. The official label does not typically specify a tapering schedule, and treatment completion should adhere to the duration prescribed by the healthcare professional.

Q: Does Sefin affect sleep patterns?

A: Some adverse reactions involving the nervous system have been reported. While specific sleep disorders are not listed as common side effects, any effects on the nervous system could potentially interfere with normal sleep patterns.

Q: Are there any specific laboratory tests needed while taking Sefin?

A: Official safety information recommends that patients with pre-existing kidney issues undergo periodic monitoring of renal function. Also, the drug is known to interfere with certain specific laboratory tests, such as the direct Coombs' test.

Q: What is the typical duration of treatment with Sefin?

A: Treatment is typically continued for a minimum of 48 to 72 hours after the patient becomes asymptomatic (symptom-free). For certain infections, such as those caused by streptococcus, the mandated treatment course is a minimum of 10 days.

How should Sefin be stored and disposed of?

How to Store and Dispose of Sefin?

The Sefin (ceftriaxone) dry powder for injection must be stored below 25 C (77 F) and protected from light by keeping the vial in the original carton. It is essential to keep Sefin out of the reach of children.

Once the powder is reconstituted, the solution has a limited stability and must be used within specific timeframes. The reconstituted product is stable for 6 hours at room temperature or up to 24 hours when refrigerated (2 C to 8 C). Any portion of the solution that is not used after this stability period must be discarded.

Handling Requirements state that Sefin must not be mixed or co-administered with any calcium-containing solutions due to the risk of precipitation. All unused medication, expired vials, and associated materials must be disposed of according to local pharmaceutical waste regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Sefin found in:

A-Z Index: